$Red Cat Holdings (RCAT.US)$ every one of these stock charts on a daily basis looks virtually identical.
they all started rallying last November they peaked either end of December early January and they have pretty much eliminated that entire bubble. most have consolidated at or near the 250 day moving average.
you can pull up virtually any technology company any small cap in an industry that was in play and all of the charts look the same

$Recursion Pharmaceuticals (RXRX.US)$ Cathy Woods purchased 54,000 shares yesterday

This Stock Could Be the Most Undervalued Buy Right Now – Analysts Say Buy
Esperion Therapeutics (ESPR.US): A Top Acquisition Target with Massive Growth Potential
Esperion Therapeutics is emerging as a prime acquisition candidate in the cholesterol-lowering space, thanks to its innovative drug portfolio and rapid sales growth. The company is developing a triple-combination pill that could dominate the LDL-lowering market, further strengthening its ...

$TransMedics (TMDX.US)$ Reversal ? lets wait n watch.

$The Honest (HNST.US)$ Getting rejected from the confluence of resistance. Highly likely to go down to fill the gap. Get yo cash ready.

$Recursion Pharmaceuticals (RXRX.US)$ we have earnings later this week
if you take a look at the past several earnings releases it's a non-event it's really non-material to the movement of the stock.
future is going to be their innovations not what their present revenue model is as long as they have sufficient cash in hand and they're not going to drop some rock on our heads by doing an offering out of the blue.. really comes down to these are the type of companies that you want to own that hav...

$Esperion Therapeutics (ESPR.US)$
Probably gonna close this position too.
25% Canadian tariff exposes ESPR to $12-15M cost increase annually.
Pivot to India for supply, unfortunately Novo Nordisk and other giants did too, resulting in a 14-18M backlog. This will delay their shift to at least 2026, so that's at least 1 year of exposure.
58% Dependence on Medicare funds.